Jean Thomas Vilquin
- Myoblast transplantation: clinical trials and perspectives. Mini-reviewJ T Vilquin
INSERM U582, Association Institut de Myologie, Universite Pierre et Marie Curie, Paris
Acta Myol 24:119-27. 2005..Some solutions are emerging, which recently allowed the set-up of new clinical trials in dedicated indications...
- Mesenchymal stem cells in bone and cartilage repair: current statusJean Thomas Vilquin
Groupe Hospitalier Pitie Salpetriere, INSERM U582, Association Institut de Myologie, IFR14, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
Regen Med 1:589-604. 2006..They also consider the stringent conditions, constraints and considerations necessary to take cell-mediated therapy from bench to bedside...
- [Cell transplantation in heart failure management]Jean Thomas Vilquin
INSERM U 582, Institut de Myologie, Groupe Hospitalier Pitie Salpetriere, Batiment Babinski, 75651 Paris Cedex 13, France
Med Sci (Paris) 20:651-62. 2004..High quality clinical trials supported by strong pre-clinical data will help to evaluate the role of cell therapy as a potential treatment for heart failure...
- Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathyAlbert A Hagege
Assistance Publique Hopitaux de Paris, Department of Cardiology, Hôpital Européen Georges Pompidou and INSERM EMI 16, Necker Paris V University, Paris, France
Lancet 361:491-2. 2003..6%, respectively, in skeletal muscle). Myoblast grafts can survive and show a switch to slow-twitch fibres, which might allow sustained improvement in cardiac function...
- Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunctionPhilippe Menasche
Assistance Publique Hopitaux de Paris, Department of Cardiovascular Surgery B, Hopital Bichat, Paris, France
J Am Coll Cardiol 41:1078-83. 2003..This phase I trial was designed to assess the feasibility and safety of autologous skeletal myoblast transplantation in patients with severe ischemic cardiomyopathy...
- Long-term (1 year) functional and histological results of autologous skeletal muscle cells transplantation in ratNawwar Al Attar
Department of Cardiovascular Surgery and INSERM U 572, Hopital Europeen Georges Pompidou, Paris, France
Cardiovasc Res 58:142-8. 2003..The present experiments were designed to assess the long-term effects of the procedure...
- Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patientsAlbert A Hagege
Universite Paris Descartes, Faculte de Medecine, Paris, France
Circulation 114:I108-13. 2006..Short-term follow-up (FU) studies have suggested that a similar benefit could clinically occur despite an increased risk of LV arrhythmias...
- Characterization of distinct mesenchymal-like cell populations from human skeletal muscle in situ and in vitroSéverine Lecourt
UPMC AIM UMR S 974, Groupe Hospitalier Pitie Salpetriere, Paris, France
Exp Cell Res 316:2513-26. 2010..These results underline the diversity of human muscle cells, and the shared or restricted commitment abilities of the main lineages under defined conditions...
- Can cold or heat shock improve skeletal myoblast engraftment in infarcted myocardium?Agnes Maurel
1 INSERM U633, Laboratoire d Etude des Greffes et Prothèses Cardiaques, Hopital Broussais, Paris, France
Transplantation 80:660-5. 2005....
- Does the functional efficacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy?Julia Pouly
INSERM U582, Institute of Myology, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
Circulation 110:1626-31. 2004..To address this issue, we tested SM transplantation in CHF147 Syrian hamsters, a strain characterized by a delta-sarcoglycan deficiency that phenotypically features the human setting of primary dilated cardiomyopathy...
- Skeletal myoblast transplantation through a catheter-based coronary sinus approach: an effective means of improving function of infarcted myocardiumCamille Brasselet
Assistance Publique Hopitaux de Paris, Department of Cardiology, Hôpital Européen Georges Pompidou et Faculté de Médecine René Descartes, Universite Paris V, Paris, France
Eur Heart J 26:1551-6. 2005..This study was designed to assess the functional effects of a transvenous coronary sinus technique of skeletal myoblast delivery in infarcted myocardium...
- Cell therapy for muscular dystrophies: advances and challengesJean Thomas Vilquin
UPMC UM 76, Groupe Hospitalier Pitie Salpetriere, Paris, France
Curr Opin Organ Transplant 16:640-9. 2011..This article reviews recent problems including the identification of new putative cellular candidates, the combination of complementary genetic or pharmacological therapeutic approaches, and the set up of clinical trials...
- Aldehyde dehydrogenase activity identifies a population of human skeletal muscle cells with high myogenic capacitiesKarine Vauchez
Inserm U974, Paris, France
Mol Ther 17:1948-58. 2009..Our results suggest that ALDH activity is a novel marker for a population of new human skeletal muscle progenitors presenting a potential for cell biology and cell therapy...
- Distinction between two populations of islet-1-positive cells in hearts of different murine strainsPatricia Khattar
UPMC AIM UMR S 974, Groupe Hospitalier Pitie Salpetriere, Paris, France
Stem Cells Dev 20:1043-52. 2011..Our studies demonstrate that islet-1-positive cells are relatively few in number in adult murine heart, being localized in restricted and rather inaccessible areas, and can represent both neural crest and cardiomyocyte lineages...
- Spontaneous muscular dystrophy caused by a retrotransposal insertion in the mouse laminin alpha2 chain geneSylvie Besse
INSERM U523, Institut de Myologie, IFR Coeur Muscle et Vaisseaux no 14, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651, Paris Cedex 13, France
Neuromuscul Disord 13:216-22. 2003..The dy(Pas)/dy(Pas) mouse is thus the first spontaneous mutant with a complete laminin alpha2 chain deficiency in which the mutation has been identified...
- Electrotransfer at MR imaging: tool for optimization of gene transfer protocols--feasibility study in miceMarion Paturneau-Jouas
INSERM U 582, Institut de Myologie, Hopital de la Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris, France
Radiology 228:768-75. 2003....
- Myoblasts and embryonic stem cells differentially engraft in a mouse model of genetic dilated cardiomyopathyCyril Catelain
1 UPMC UM 76, Groupe Hospitalier Pitie Salpetriere, Paris, France 2 INSERM U974, Groupe Hospitalier Pitie Salpetriere, Paris, France 3 CNRS UMR 7215, Groupe Hospitalier Pitie Salpetriere, Paris, France 4 Association Institute of Myology, Groupe Hospitalier Pitie Salpetriere, Paris, France 5 Groupe Hospitalier Pitié Salpêtrière, Paris, France
Mol Ther 21:1064-75. 2013..These data suggest that committed ESC fail to integrate in DCM where scar tissue is absent to provide the appropriate niche, whereas the functional benefits of Mb transplantation might extend to nonischemic cardiomyopathy...
- Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardiumOnnik Agbulut
INSERM U572, Hopital Lariboisiere, Paris, France
J Am Coll Cardiol 44:458-63. 2004..The present study was designed as a face-to-face functional comparison of human skeletal myoblasts (SMs) and CD133(+) bone marrow-derived hematopoietic progenitors in an animal model of semichronic myocardial infarction...
- Building the translational highway: toward new partnerships between academia and the private sectorKetty Schwartz
Unité INSERM 582, Institut de Myologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
Nat Med 9:493-5. 2003
- Autologous myoblast transplantation for chronic ischemic mitral regurgitationEmmanuel Messas
Universite Rene Descartes Paris 5, Faculté de médecine René Descartes Paris 5, Paris, France
J Am Coll Cardiol 47:2086-93. 2006..This study was designed to assess whether post-myocardial infarction (MI) in-scar transplantation of skeletal myoblasts (SM) could reduce chronic ischemic mitral regurgitation (MR) by decreasing left ventricular (LV) remodeling...
- Ex vivo generation of mature and functional human smooth muscle cells differentiated from skeletal myoblastsSophie Le Ricousse-Roussanne
Institut des Vaisseaux et du Sang et Centre de Recherche Cardiovasculaire, INSERM U689, Paris, France
Exp Cell Res 313:1337-46. 2007..Based on the easily available tissue source and their differentiation into functional SMCs, these data argue that skeletal myoblasts might represent an important tool for SMCs-based cell therapy...
- Current advances in cell therapy strategies for muscular dystrophiesElisa Negroni
Unité Thérapies des Maladies du muscle strié, UMRS974, UPMC Universite Paris 6, UM76, Inserm U974, CNRS UMR 7215, Institut de Myologie, Paris, France
Expert Opin Biol Ther 11:157-76. 2011..Cell therapy consists of delivering myogenic precursor cells to damaged tissue for the complementation of missing proteins and/or the regeneration of new muscle fibres...
- Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their hostBertrand Leobon
Laboratory of Neurophysiology, Institut National de la Sante et de la Recherche Medicale, EPI 0002, Centre National de la Recherche Scientifique FRE2500, Ecole Superieure de Physique et Chimie Industrielles de la Ville de Paris, 75231 Paris, France
Proc Natl Acad Sci U S A 100:7808-11. 2003..We conclude that mechanisms other than electromechanical coupling between grafted and host cells are involved in the improvement of cardiac function...
- [The possible place of autologus cell therapy in facioscapulohumeral muscular dystrophy]Claude Desnuelle
Centre de Reference pour les Maladies Neuromusculaires CHU de Nice Groupe Hospitalier l Archet, BP 3079, 06202 Nice cedex 03 et INSERM U 638
Bull Acad Natl Med 189:697-713; discussion 713-4. 2005..These results indicate that myoblasts taken from unaffected muscle of patients with FSHD warrant testing in a human cell therapy trial...
- A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac musclesBruno Pitard
INSERM U533, Faculte de Medecine, 44000 Nantes, France
Hum Gene Ther 13:1767-75. 2002..We propose that the PE6400 formulation could serve for the treatment of diseases primarily affecting muscle or for the expression of therapeutic proteins for local or systemic benefit...
- Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarctionSaid Ghostine
Inserm EMI 0016, Necker Paris V University and Department of Cardiology 1, Hopital Europeen Georges Pompidou, France
Circulation 106:I131-6. 2002..Transplantation (Tx) of skeletal myoblasts (SM) within an infarcted myocardium improves global left ventricular (LV) function, although a direct systolic effect remains controversial...
- The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantationPhilippe Menasche
Département de Chirurgie Cardio vasculaire, Hopital Europeen Georges Pompidou, 20, rue Leblanc, 75015 Paris, France
Circulation 117:1189-200. 2008..Phase I clinical studies have demonstrated the feasibility of implanting autologous skeletal myoblasts in postinfarction scars. However, they have failed to determine whether this procedure was functionally effective and arrhythmogenic...